Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH

Journal of Clinical Oncology

Volumn 18, Issue 21, 2000, Pages 3633-3642

  Gutierrez, Martin ^a   Chabner, Bruce A ^a   Pearson, Debra ^a   Steinberg, Seth M ^a   Jaffe, Elaine S ^a   Cheson, Bruce D ^a   Fojo, Antonio ^a   Wilson, Wyndham H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; VINCRISTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT INDICATION;

EID: 0034329772     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.21.3633     Document Type: Article

References (34)

1. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphomas
2. Recombinant interferon alfa- 2b with a regimen containing doxombicin in patients with advanced follicular lymphoma
3. IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy
4. Results of MIME salvage regimen for recurrent or refractory lymphoma
5. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
6. CEPP(B): An effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma
7. ESHAP-An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study
8. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate
9. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines
10. Cell cycle control and cancer chemotherapy
11. Checkpoints of dueling dimers foil death wishes
12. Dysregulation of apoptosis in cancer
13. EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma
14. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy
15. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors
16. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection
17. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
18. Non-parametric estimation from incomplete observations
19. Evaluation of survival data and two new rank order statistics arising in its consideration
20. Regression models and life tables
21. Chi-square tests with one degree of freedom: Extensions of the Mantel-Haenszel procedure
22. A distribution-free K-sample test against ordered alternatives
23. A sharper Bonferroni procedure for multiple results obtained
24. Phase II and doseescalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas
25. High-dose chemo-therapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma
26. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
27. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
28. Risk factors for doxorubicin-induced congestive heart failure
29. Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation
30. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
31. A phase-II trial of infusional etoposide, vincristine, and doxorubicin with bolus cyclophosphamide (EPOCH) along with filgrastim support in patients with relapsed Hodgkin's and non-Hodgkin's lymphomas
32. P-glycoprotein expression in malignant lymphoma and reversal of clinical drag resistance with chemotherapy plus high-dose verapamil
33. Relationship of p53, bcl-2 and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas